Pfizer Reports Positive Data, Priority Review for Talzenna/X

By Colin Kellaher


Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease... | February 16, 2023

Related Keywords

New York , United States , Colin Kellaher , Pfizer , Pfizer Inc , Drug Administration , Dow Jones , Nc Stock Exchange , News , Information , Press Release , Y , Colin , Kellaher , N , Hursday , Aid , Hase , , Study , Combining , Its , Drug , Talzenna , Ith , Xtandi , Howed , Reduction , The , Risk , F Pfe Us7170811035 ,